Trametinib + DABRAFENIB for ameloblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Jan 2023: Trial started, NCT06653517
  2. 22 Oct 2024: Trial registered, NCT06653517

The trials

NCT06653517: Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma

State
Under way
Phase
Phase 2
People
12 planned
Started
1 Jan 2023
Primary completion
31 Dec 2026
Arms
Dabrafenib and Trametinib Treatment Arm
Results
None posted
  1. 1 Jan 2023: Trial started
  2. 22 Oct 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.